Cleveland BioLabs (CBLI) Earning Critical Media Coverage, Report Shows
News articles about Cleveland BioLabs (NASDAQ:CBLI) have been trending negative recently, according to AlphaOne Sentiment Analysis. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cleveland BioLabs earned a news impact score of -0.29 on AlphaOne’s scale. AlphaOne also gave news coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Alpha One’s analysis:
- Governments Looking at Cleveland Biolabs Radiation Countermeasure (finance.yahoo.com)
- Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX… (finanznachrichten.de)
- ETFs with exposure to Cleveland BioLabs, Inc. : April 19, 2017 (finance.yahoo.com)
- Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus (investorplace.com)
- Cleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review (streetinsider.com)
Cleveland BioLabs (NASDAQ:CBLI) opened at 4.27 on Friday. The company has a 50-day moving average of $1.92 and a 200 day moving average of $1.70. Cleveland BioLabs has a 12 month low of $1.22 and a 12 month high of $5.55. The company’s market cap is $46.91 million.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/04/21/cleveland-biolabs-cbli-earning-critical-media-coverage-report-shows.html
Cleveland BioLabs (NASDAQ:CBLI) last issued its quarterly earnings data on Wednesday, February 22nd. The biotechnology company reported ($0.11) earnings per share for the quarter. The company had revenue of $0.99 million for the quarter. Cleveland BioLabs had a negative net margin of 75.04% and a negative return on equity of 21.29%. On average, equities analysts forecast that Cleveland BioLabs will post ($0.16) earnings per share for the current fiscal year.
About Cleveland BioLabs
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.